Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics (ALLO) announced that Executive Vice President and Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026.
Rhea-AI Summary
Allogene Therapeutics (ALLO) announced that Executive Vice President and Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026. He will continue to lead the finance organization until his retirement while the company conducts an external search for his successor.
The chief executive officer praised Mr. Parker’s financial leadership and role during a pivotal phase in Allogene’s evolution. Mr. Parker stated he is proud of the company’s accomplishments, remains confident in its strategy and pipeline, and plans to support a smooth transition over the coming months.
Positive
- Planned CFO retirement effective November 6, 2026 allows orderly transition
- Outgoing CFO will lead finance team through transition period
- External search for new CFO already underway
- CFO expresses continued confidence in Allogene’s strategy and pipeline
Negative
- Retirement of Executive Vice President and CFO Geoffrey Parker
- No successor named yet for the CFO role
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization through his retirement date as the Company conducts an external search for his successor.
"Geoff has been a trusted and important leader within Allogene through a pivotal period in the Company’s evolution," said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene." His financial leadership and commitment to the organization have helped position Allogene to advance our programs with discipline and focus. We are grateful for his many contributions and wish him the very best in retirement."
“I am proud of what we have accomplished together and grateful to have worked alongside such a talented and dedicated team,” said Mr. Parker. “I remain deeply confident in Allogene’s strategy and the potential of its pipeline, and I look forward to supporting a smooth transition over the coming months.”
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
